11 months ago
Blue Jet Healthcare Investors Await Margin Recovery
Blue Jet Healthcare's stock price has decreased recently.
The company makes ingredients for medical imaging and sweeteners, like saccharin.
The company is working to make more profitable products and cut costs by producing its own raw materials.
They are expanding their manufacturing capacity.
Over the past four years, revenue and profit have more than doubled.
Investors are now waiting to see if profit margins will improve again.
If the company succeeds in its plans, the stock may increase in value.
Blue Jet Healthcare's stock has fallen approximately 40% from its 52-week high.
EBITDA margin dropped to 34% in Q1FY26 due to inventory adjustments.
The company focuses on contract manufacturing for contrast media and high-intensity sweeteners.
Blue Jet is moving up the value chain and backward integrating at its Mahad facility.
Revenue and profit after tax more than doubled from FY21 to FY25.
- Who
- Blue Jet Healthcare and its investors
- What
- Investors are awaiting margin recovery after a stock price decline
- Where
- Mahad, Maharashtra facility
- When
- Stock declined after June quarter (Q1FY26) results were announced
- Why
- Due to an EBITDA margin drop and focus on high-margin areas
Key facts
- Stock Price Decline
- 40% from 52-week high
- 52-Week High
- ₹1,027.80
- EBITDA Margin (Q1FY26)
- 34%
- Contract Manufacturing Focus
- Contrast media intermediates and high-intensity sweeteners
- Key Clients
- GE Healthcare, Colgate-Palmolive, Unilever
- Revenue FY25
- ₹1,030 crore
- Profit After Tax FY25
- ₹305 crore
- Capacity Increase
- Planning to add another 1,000KL





